Parkinson’s Disease Therapeutics Market 2022 New Technological Development Projecting Massive Growth till 2026

Parkinson’s disease is a central nervous system disorder that affects motor neuron activities and is characterised by tremor, rigidity, dementia, and depression, among other symptoms. According to the GDB 2013 Mortality and Causes of Death Collaborators report, 53 million people had Parkinson’s disease in 2013, and the disease killed 103,000 people worldwide.

Parkinson’s disease risk increases with age, and the disease primarily affects people over the age of 50. Parkinson’s disease treatment is primarily symptomatic, with no curative options available. The primary goal of Parkinson’s disease treatment is to control signs and symptoms such as shakiness in the hands, difficulty walking, slowness of movement, and so on.

The therapeutic approach for each individual differs depending on his or her symptoms. Medication and surgery are both options for treatment. The combination of levodopa and carbidopa is regarded as the gold standard for symptomatic treatment of Parkinson’s disease. Deep brain stimulation and Carbidopa/levodopa enteral suspension therapy are surgical treatment options.

Surgical therapy, on the other hand, is only effective in patients who have previously responded to Levodopa therapy. Cycloset, Parlodel (Bromocriptine Mesylate), Requip (ropinirole), Rytary, Azilect, Northera, Stalevo, Comtess/Comtan, and other drugs are commercially available for the treatment of Parkinson’s disease. Over the last decade, significant progress has been made in Parkinson’s disease treatment, including the identification of new therapeutic targets through genetic research, understanding the common mutations that contribute to Parkinson’s disease, and so on.

For Critical Insights, Request for Sample@
https://www.futuremarketinsights.com/reports/sample/rep-gb-2527

Parkinson’s disease Therapeutics Market: Drivers and RestraintsRecent advancements in Parkinson’s disease therapeutics, such as combination therapies to extend the action of continuous dopaminergic stimulation drugs, approval for Neurostimulation devices, neuroprotective therapies to slow disease progression, gene therapy, neural transplantation, and so on, are expected to drive massive growth in the global Parkinson’s disease therapeutics market over the forecast period. Furthermore, the world’s ageing population and the prevalence of Parkinsonism are driving demand for Parkinson’s disease therapeutics.

However, generic erosion caused by the expiration of patents for several drugs such as Rytary, Stalevo (2012), Azilect (2017), Comtan (exclusivity expired in 2013), and others would stymie the global Parkinson’s disease therapeutics market’s growth.

Parkinson’s disease Therapeutics Market: OverviewThe global Parkinson’s disease therapeutics market is expected to grow at a healthy CAGR during the forecast period, as new therapies such as repetitive transcranial magnetic stimulation device, adipose derived stem cell therapy, non-invasive Neurostimulation device, and others are expected to enter the market.

The increasing burden of Parkinson’s disease management on healthcare systems in major countries such as the United States and the United Kingdom would stimulate the government’s exhaustive efforts to accelerate R&D in Parkinson’s disease therapeutics. For example, over 40 medicines are being developed in the United States for the treatment and diagnosis of Parkinson’s disease, many of which have received fast track designation from the U.S. FDA.

Parkinson’s disease Therapeutics Market: Regional OverviewNorth America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, the Middle East, and Africa comprise the global Parkinson’s disease therapeutics market. Because of favourable reimbursement policies and the disease’s high prevalence, North America has traditionally dominated the global market for Parkinson’s disease therapeutics. Each year, approximately 60,000 Americans are diagnosed with Parkinson’s disease, according to the Parkinson’s Disease Foundation (PDF). Europe is expected to hold the second largest share of the global market as a result of increased R&D efforts by the region’s key players.

Parkinson’s disease Therapeutics Market: Key PlayersGlaxoSmithKline Plc., Salix Pharmaceuticals, mpax Laboratories, Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Orion Corporation, Mylan N.V., and others are among the key players in the global Parkinson’s disease therapeutics market, while generic players include Par Pharmaceutical, Cipla Inc., Daiichi Sankyo, Apotex Inc., Wockhardt Limited, and others.

Inquire Before Buying Research Report@
https://www.futuremarketinsights.com/askus/rep-gb-2527

Parkinson’s disease Therapeutics Market: SegmentationThe global Parkinson’s disease therapeutics market is classified on the basis of treatment type, end user and geography.

Based on treatment type, the global Parkinson’s disease therapeutics market is segmented into the following:

• Medications
• Dopamine Precursors
• Peripheral Decarboxylase Inhibitors
• COMT Inhibitors
• MAO Inhibitors
• Others (anticholinergics, antihistaminics etc.)
• Medical Devices
• Deep Brain Stimulation (DBS) Devices
• Carbidopa/Levodopa Enteral Suspension (Duopa) delivery devices

Based on end user, the global Parkinson’s disease therapeutics market is segmented into the following:

• Hospitals
• Clinics
• Homecare Settings

Read Related Reports:

https://degentevakana.com/blogs/view/121254
https://vocal.media/stories/hypoparathyroidism-treatment-market-2022-scope-of-current-and-future-industry-2031
https://www.dronepilotlari.com/blogs/52528/Saudi-Arabia-Pharmaceutical-Market-2022-Key-Players-SWOT-Analysis-Key
https://vocal.media/stories/frontotemporal-disorders-treatment-market-2022-scope-of-current-and-future-industry-2028

About FMI                     

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:                                        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
Report: https://www.futuremarketinsights.com/reports/parkinsons-disease-therapeutics-market
For Sales Enquiries: sales@futuremarketinsights.com
Browse latest Market Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs